Biostax Corp (BTAX)

[Herold]

Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that the Company and Cytocom Inc., a leading biopharmaceutical company developing next generation therapeutics that target immune restoration and homeostasis, will host an investor call and live webcast on Wednesday, July 7 at 8:30 a.m. ET.

https://mma.prnewswire.com/media/1440125/Cleveland_BioLabs.jpg

During the call, Michael K. Handley, President and Chief Executive Officer of Cytocom, and members of the Cleveland BioLabs Board of Directors will discuss the results of the vote on the merger transaction, scheduled to take place July 6, 2021, during a Special Meeting of Cleveland BioLabs shareholders. Mr. Handley will also discuss the strategic vision for the combined companies including the opportunities in COVID-19, Crohn's disease, pancreatic cancer, hematology, and acute radiation syndrome. The company is developing therapies and plans to launch therapies into the $48.7 billion gastrointestinal market, the $84.3 billion therapeutic oncology market, the $82.5 billion hematology market and the $125.0 billion autoimmune market. The combined company could have the broadest Toll-like receptor therapeutic platform in the industry, allowing it to potentially treat a multitude of immune-related diseases and significantly expand the size of its total addressable markets.